10January

Fiasp® (fast-acting insulin aspart) approved in Europe ... Read more

09January

Novo Nordisk and Glooko partner to develop digital health solutions for people w ... Read more

16January

Novo Nordisk A/S - Share repurchase programme ... Read more

10January

Fiasp® (fast-acting insulin aspart) approved in Europe ... Read more

09January

Novo Nordisk A/S - Share repurchase programme ... Read more

02January

Novo Nordisk A/S - Status regarding Novo Nordisk's holding of its own shares (31 ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations

 

Novo Nordisk News


Fiasp® (fast-acting insulin aspart) approved in Europe

10 January - the European Commission has granted marketing authorisation for Fiasp® for the treatment of diabetes in adults. “Fiasp® is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals. The incremental benefits with Fiasp® are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. 

Read the press release

 


Novo Nordisk and Glooko partner to develop digital health solutions 

Novo Nordisk and Glooko will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. Read all the details



Cities changing diabetes in Shanghai

Wake-up call for urban health!

12 October - Monday 17 October, governments and international bodies met for Habitat III in Quito, Ecuador – a historic summit that would define the big priorities for urbanisation in the ‘New Urban Agenda’. In an open letter in the New York Times, the mayors, city and health leaders of six major cities expressed their concern about the urban crisis the world is just starting to wake up to.  

Read the open letter

 


Sarah Ahmed from Ethopia has type 1 diabetes

Novo Nordisk committed to guarantee access to insulin

22 September - Access to reliable and affordable supplies of insulin is a challenge for many in the poorest nations in the world. Lars Rebien Sørensen has pledged to extend the current programme from 2001 and expand Novo Nordisk's commitment to supply human insulin at fixed low prices to the Least Developed Countries and low-income nations; the programme will now be extended to cover selected organisations providing relief in humanitarian situations.

Read all the details about Novo Nordisk's programme on access to insulin

The diabetes challenge - get an overview of Novo Nordisk's commitment 


World Diabetes Day in a War Zone

What do you do on World Diabetes Day when you have an inhuman situation in a war zone? Novo Nordisk employees in Libya give you insights from the field.

Read the whole story

WDD in a war zone

The digital health connection in Africa

A commitment to children with type 1 diabetes and the growing uptake and use of mobile technology in Africa were the catalysts for action on the ground – and in cyberspace.

Read the story

Digital health in Africa

The one rule we have to break!

Watch the film featuring the 'Rule of Halves' illustrating the challenges that need to be overcome to get diabetes under control. Or see some of the Leading Lights movies with six urbanisation experts giving their perspectives on #urbandiabetes.

 

This film features the 'Rule of Halves' illustrating the challenges that need to be overcome to get diabetes under control
This film features the 'Rule of Halves' illustrating the challenges that need to be overcome to get diabetes under control
This film features the 'Rule of Halves' illustrating the challenges that need to be overcome to get diabetes under control

Calendar

Full-year results 2017
02FebruaryDenmark

Our carbon footprint

How can Novo Nordisk play a role in offering solutions that are good for people’s health and the planet? Read what CEO Lars Fruergaard Jørgensen says and how we can take carbon emissions to the product level.


An exceptional patient entrepreneur!

Winner of Lyfebulb award

Dec '16 - Patient entrepreneur Brianna Wolin was selected as winner of the Lyfebulb-Novo Nordisk Innovation Award: 'Find Your Ditto' - a mobile platform which connects patients living with the same chronic illness for on-demand, in-person peer support.

Read more about the Lyfebulb-Novo Nordisk partnership


LEADER clinical trial backgrounder

What are cardiovascular outcomes trials? What's LEADER? See and read about all the details.


Growth challenges


A national strategy for Danish life science is needed; read about the potential of the future - an even smarter Denmark, world-class knowhow, more Danish entrepreneurship - an even more attractive Denmark. Read the analysis in Danish or English.


Novo Nordisk in brief


Get an instant impression of what Novo Nordisk is about, see the numbers and read about partnership activities that drive change. 

Download Novo Nordisk backgrounder 


Novo Nordisk Stories

Views on obesity

The view on obesity is slowly changing, but there are still many myths about the disease that all contribute to creating barriers for proper treatment.

Read the story

Theme: Innovation